The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...

Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to ...

Three stocks that did well during the last big bear market in 2022 are AbbVie ( ABBV +0.15%), Eli Lilly ( LLY +2.09%), and ...

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

Tirzepatide starts working quickly. You might notice less hunger in a few days or weeks. Average weight loss in 3 weeks is ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...